Daniel Welch

Executive Partner, Private Equity

Dan joined Sofinnova as an Executive Partner in 2015. He brings significant management expertise to support the building of innovative Life Science companies from clinical stage drug development to large-scale commercialization. In addition, his experience is vital to our portfolio companies in both operations and building complex international businesses. Dan is a board director of Seattle Genetics (SGEN), Ultragenyx (RARE), Intercept (ICPT), and Avexis (AVXS).

Prior to Sofinnova, Dan was the Chairman, CEO, and President of InterMune (ITMN). He led a comprehensive company turn-around, refocusing their development efforts. During his tenure, InterMune secured registration of Esbriet, the first medicine approved for idiopathic pulmonary fibrosis in Europe and the United States. Dan built the InterMune Development and Commercial Teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune for $8.3B, a 60% premium to the pre-deal price. Prior to Intermune, Dan served as Chairman and CEO of Triangle Pharmaceuticals, which was acquired by Gilead Sciences in 2003 for $500M. From October 2000 to June 2002, he served as President of the Pharmaceutical Division of Elan (acquired by Perrigo). From September 1987 to August 2000, Dan served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin, and Avapro as both VP of Worldwide Marketing and COO of the U.S. business. From November 1980 to September 1987, Dan was with American Critical Care, a division of American Hospital Supply.

Dan received his MBA from the University of North Carolina and holds a BS from the University of Miami.

Assistant: Lesley Weber

Email: lesley@sofinnova.com